miDIAGNOSTICS has established a collaboration with emocha Mobile Health from Baltimore, USA, to embed its integrated diagnostic solutions for the point-of-need in the latter mobile applications platform.
A Johns Hopkins University start-up company, emocha has developed a platform of digital mobile applications designed to streamline the continuum of care. The goal of the collaboration is to enable mobile health solutions based on the miniaturised products for point-of-need currently being developed by miDIAGNOSTICS.
miDIAGNOSTICS aims to develop diagnostic tests integrated in silicon chips. These will act as miniaturized labs, able to detect cells, proteins, nucleic acids, or small molecules from a tiny volume of body fluid. The results and data from these complex but easy to use tests will be available in minutes.
That is where the emocha platform will come in, connecting the miDIAGNOSTICS’ products and their results to the laptops, tablets or smartphones of patients and caregivers, making them into a mobile health solution for diagnostics at the point-of-need, everywhere and at any time.
Hilja Ibert, CEO of miDIAGNOSTICS, explained: “emocha adds mobile data management to our diagnostic devices. They will complement our products with a mobile application, cloud infrastructure, and dashboards. The mobile application will give users easy access to a diagnostic device to initiate tests and view results on their mobile devices.
“The cloud infrastructure is the central hub transforming future miDIAGNOSTICS’ products into impactful mobile health solutions that links patient results to providers and health system electronic records. Finally, the dashboard will offer a customisable view of test results, allowing consolidation of tests and data analysis.”
emocha Mobile Health was founded based on technology licensed from Johns Hopkins University. “Our mission is to help transform public health through mobile technology,” said Sebastian Seiguer, emocha's co-founder and CEO.
“We are very excited that miDIAGNOSTICS has chosen us as their digital health partner. Their product vision and breakthrough technology are a perfect match to our platform. We hope to be able to add miDIAGNOSTICS point of need testing to our mobile health interventions for a variety of use cases, like Hepatitis C medication adherence. Care has shifted rapidly to the outpatient setting, and our integrated solutions will enable providers to strongly support patients wherever they may be.”
Peter Peumans, VP and programme director life science technologies at imec added: “miDIAGNOSTICS technology builds on the expertise of imec and Johns Hopkins, leading research institutions in the field of nanotechnology and medicine.
“Adding emocha Mobile Health as a collaborator, we have chosen a top expert in the field of mobile health, connectivity and data management. Together, we will deliver our vision: globally shifting the way in which individuals and communities manage their healthcare.”